The recent ruling (21 November 2018) of the European Court of Justice puts an end to the dispute over the off-label use of bevacizumab for age-related macular degeneration.
The recent ruling (21 November 2018) of the European Court of Justice puts an end to the dispute over the off-label use of bevacizumab for age-related macular degeneration.
09 December 2019 FDA | 09 December 2019 FDA |
09 December 2019 CADTH | 02 December 2019 FDA |
26 November 2019 FDA | 19 November 2019 FDA |
19 November 2019 FDA | 19 November 2019 FDA |
15 November 2019 FDA | 15 November 2019 FDA |